Comparison · NCT00082173-a0bfe2b5
Experimental Arm vs Control Arm: Proportion of Patients With Grade 3 or 4 Adverse Reactions Attributable to Study Medications
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Experimental Arm vs Control Arm: Proportion of Patients With Grade 3 or 4 Adverse Reactions Attributable to Study Medications. Trial comparisons, record NCT00082173-a0bfe2b5. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00082173-a0bfe2b5
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0 | 0 | 0.0493 | wilson | |
| Risk in group 2 | 0 | 0 | 0.0507 | wilson | |
| Risk difference, group 1 minus group 2 | 0 | -0.0507 | 0.0493 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat | from the risk difference interval | the two groups' risks are equal |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: control.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Experimental Arm | INH 300mg/RIF 600mg/PZA 20mg/kg/MOX 400mg/EMB placebo once daily for 8 weeks | 0 | 74 | OG000 |
| Group 2 | Control Arm | INH 300mg/RIF 600mg/PZA 20mg/kg/MOX placebo/EMB 15-20mg/kg once daily for 8 weeks | 0 | 72 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Proportion of Patients With Grade 3 or 4 Adverse Reactions Attributable to Study Medications
- Description
- Proportion of patients with Grade 3 or 4 adverse reactions attributable to study medications
- Time frame
- 8 weeks
- Population
- DAIDS Table of Adverse Events
Source ClinicalTrials.gov
Trial
- Title
- Moxifloxacin As Part of a Multi-Drug Regimen For Tuberculosis
- NCT number
- NCT00082173
- Phases
- PHASE2
- Conditions
- Tuberculosis
- Interventions
- Moxifloxacin
- Lead sponsor
- Johns Hopkins University
- Results first posted
- 2013-05-22
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00082173?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00082173-a0bfe2b5